AstraZeneca Beefs Up in Metabolic Disease, Paying $1.2B to Partner on CSPC Obesity & Diabetes Meds
AstraZeneca is expanding its prospects in cardiometabolic disease, paying $1.2 billion to begin a partnership on eight programs that include obesity drug candidates with potential advantages over currently available products and clinical-stage medicines in …